{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-083676","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.826437+00:00","generated_at":"2026-05-19T17:54:48.772253+00:00","sec_items":["5.07","5.02","1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FibroGen shareholders approve reverse stock split; appoints Michael Kauffman to board","bullets":["Shareholders approved reverse stock split (1:10-1:25) to meet Nasdaq listing requirement; 85% voted in favor.","Jeffrey L. Edwards re-elected as Class II director with 92.25% of votes cast.","Dr. Michael Kauffman appointed to board, will serve on Audit and Compensation Committees; term expires 2026.","Director Aoife Brennan resigned effective June 4, 2025, no disagreement with company.","Second amendment to financing agreement lowered minimum cash balance from $27M to $22.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-083676","json":"https://secwatch.observer/filing/0000950170-25-083676.json","markdown":"https://secwatch.observer/filing/0000950170-25-083676.md","text":"https://secwatch.observer/filing/0000950170-25-083676.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017025083676/0000950170-25-083676-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017025083676/fgen-20250604.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T17:54:48.772253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39d07941ef","claim":"Aoife Brennan resigned as Director at KYNTRA BIO, INC..","evidence_excerpt":"On June 4, 2025, Aoife Brennan, M.B., B.Ch. provided to the Board of Directors (the “Board”) notification of her resignation from the Board of FibroGen, effective June 4, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017025083676/0000950170-25-083676-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6e5e775c46","claim":"Michael Kauffman was appointed as Class III director at KYNTRA BIO, INC..","evidence_excerpt":"Effective June 4, 2025, the Board of the Company, upon recommendation of the Nominating and Corporate Governance Committee, appointed Michael Kauffman, M.D., Ph.D. as a Class III director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017025083676/0000950170-25-083676-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}